Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

New Covid Variant Raises Fear: Stocks to Own to Buck the Trend

Seegene (096530 KS): Recovery of Non-COVID Sales to Drive Future Growth

Equity Bottom-Up

<p>Shares of Seegene (096530 KS) are trading near 52-week low. The company is reporting sequential decline in revenue due to decelerating COVID-19 PCR testing volume in European countries prior to the unexpected virus variants outbreak. Such continuous uncertainties may have resulted inventory burdens on customer end and affected to performance of Q2. Meanwhile, the proportion of COVID testing reagents sales over the total sales has been dropped to 65% in H1 2021 from 67% in 2020. However, new COVID-19 cases, especially delta variant are steadily increasing in Europe since Q3. The trend continues in early Q4 also. This may lead to a rebound in COVID-19 reagent revenue for Seegene. Management expects as demand for screenings increases in Asian countries including South Korea, Latin America, and Europe, where COVID-19 cases are growing exponentially due to the delta variant, sales in Q3 are expected to surpass that of Q2. Early trends from other global COVID testing majors enhance our conviction on COVID-19 testing revenue recovery.  </p>

Shares of Seegene (096530 KS) are trading near 52-week low. The company is reporting sequential decline in revenue due to decelerating COVID-19 PCR testing volume in European countries prior to the unexpected virus variants outbreak. Such continuous uncertainties may have resulted inventory burdens on customer end and affected to performance of Q2. Meanwhile, the proportion of COVID testing reagents sales over the total sales has been dropped to 65% in H1 2021 from 67% in 2020. However, new COVID-19 cases, especially delta variant are steadily increasing in Europe since Q3. The trend continues in early Q4 also. This may lead to a rebound in COVID-19 reagent revenue for Seegene. Management expects as demand for screenings increases in Asian countries including South Korea, Latin America, and Europe, where COVID-19 cases are growing exponentially due to the delta variant, sales in Q3 are expected to surpass that of Q2. Early trends from other global COVID testing majors enhance our conviction on COVID-19 testing revenue recovery.  

Seegene (096530 KS): Worst Seems to Be Over; Non-COVID Revenue to Dictate Long-Term Growth

Seegene Inc

Seegene (096530 KS): Worst Seems to Be Over; Non-COVID Revenue to Dictate Long-Term Growth